A First of Its Kind Study of GCP Compliance in the Major Markets around the World.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c28468) has announced the addition of The Global GCP Compliance Report: US, EU, and Japan to their offering. The First-Ever Study of Global GCP Clinical Trial Compliance Programs and Trends! Learn what the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. , OHRP OHRP Office for Human Research Protections (subsidiary of HHS; monitors safeguards of test subjects) , and Japan's PMDA PMDA Plastics Machinery Distributors' Association (United Kingdom) PMDA Plutonium Management and Disposition Agreement (US-Russia) PMDA Pharmaceuticals and Medical Device Agency (Japan) see as the GCP compliance "hot spots" today! Developed for clinical sponsors and CRAs, clinical trial administrators, clinical compliance officers, clinical investigators and site staff, clinical QA professionals, and other clinical professionals! "By far the most comprehensive review of clinical GCP compliance trends and programs in the U.S. (FDA and OHRP), Canada, EU, UK, and Japan." -- The Journal of Clinical Research Best Practices The Global GCP Compliance Report 2006: US, EU, and Japan As clinical trials are becoming more global in nature and standards for clinical trial conduct are becoming more harmonized, this just-released report presents a first-of-its kind, systematic study of GCP compliance in the world's major markets. Gain exclusive access to detailed data analyses of GCP compliance trends internationally, profiles of GCP compliance programs within several of the world's key regulatory agencies, and in-depth interviews with GCP compliance officials and GCP field inspectors! Plus, gain access to the largest compendium of GCP compliance trends and data ever compiled! Learn exactly where regulators such as the FDA, EMEA, US OHRP, UK MHRA MHRA Medicines and Healthcare Products Regulatory Agency MHRA Modern Humanities Research Association (United Kingdom) MHRA Minnesota Human Rights Act MHRA Malta Hotels and Restaurants Association , and Japan's PMDA are finding GCP problems, and what their GCP compliance "hot spots" are today. In The Global GCP Compliance Report, you'll gain access to the following in-depth profiles, compliance data, and interviews: --FDA GCP Compliance Programs for Drugs, Biologics, and Medical Devices --Interview with the EMEA's GCP Compliance Administrator Fergus Sweeney, Ph.D. --The Largest Collection of International GCP Compliance Data Anywhere --US OHRP Compliance Program/Data for Government-sponsored Research --UK MHRA's GCP Compliance Program --Japan's PMDA's GCP Compliance Program and Trend Data --Interview with FDA Bioresearch Monitoring Specialist/Inspector Mike Rashti --Interview with FDA CDRH CDRH Center for Devices and Radiological Health (US FDA) (Devices) BIMO Director Michael Marcarelli --Interview with FDA CBER CB·er n. One that uses a CB radio. (Biologics) BIMO Branch Chief Patricia Holobaugh --Complete analyses of investigator, sponsor/monitor, and IRB IRB See: Industrial Revenue Bond GCP compliance deficiencies in warning letters/regulatory notifications --Interview with FDA's CDER BIMO Director Joanne Rhoads, M.D. --Interview with Health Canada's Good Clinical Practices Unit Coordinator Jean Saint-Pierre For more information visit http://www.researchandmarkets.com/reports/c28468 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion